Characteristics of patients with non-cancer pain and long-term prescription opioid use who have used medical versus recreational marijuana | Journal of Cannabis Research
Appels A, Mulder P. Fatigue and heart disease. The association between “vital exhaustion” and past, present and future coronary heart disease. J Psychosom Res. 1989;33(6):727–38.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79.
Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain–development of a typology of chronic pain patients. Drug Alcohol Depend. 2009;104(1–2):34–42.
Banta-Green CJ, Von Korff M, Sullivan MD, Merrill JO, Doyle SR, Saunders K. The prescribed opioids difficulties scale: a patient-centered assessment of problems and concerns. Clin J Pain. 2010;26(6):489–97.
Bobitt J, Kang H, Arora K, Bhagianadh D, Milavetz G, Kaskie B. Offering an Alternative to Persons with Chronic Pain: How Access to Cannabis May Provide an Off-Ramp from Undesired Prescription Opioid Use. Cannabis. 2023;6(2):113–22.
Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016;17(6):739–44.
Boehnke KF, Gagnier JJ, Matallana L, Williams DA. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey. J Pain. 2021;22(11):1418–28.
Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI Jr, et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol. 1994;55(2):149–58.
Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain. 2010;26(9):770–6.
Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341-ee50.
Cleeland CS. The Brief Pain Inventory User Guide. Houston: University of Texas M.D. Anderson Cancer Center; 1991.
Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007;45(10 Supl 2):S103–7.
Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007;99(1–3):83–9.
Goulet-Stock S, Rueda S, Vafaei A, Ialomiteanu A, Manthey J, Rehm J, et al. Comparing Medical and Recreational Cannabis Users on Socio-Demographic, Substance and Medication Use, and Health and Disability Characteristics. Eur Addict Res. 2017;23(3):129–35.
Hahn EA, Devellis RF, Bode RK, Garcia SF, Castel LD, Eisen SV, et al. Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. Qual Life Res. 2010;19(7):1035–44.
Hsu G, Kovacs B. Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study. BMJ. 2021;372:m4957.
Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLoS Med. 2019;16(11):e1002922.
Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20(5):309–18.
Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):19–39.
Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Soc Sci Med. 2019;233:181–92.
Marijuana Legality by State [Internet]. 2023 [cited July 14, 2023]. Available from: https://disa.com/marijuana-legality-by-state.
McGinty EE, Tormohlen KN, Seewald NJ, Bicket MC, McCourt AD, Rutkow L, et al. Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain. Ann Intern Med. 2023;176(7):904–12.
Meesters C, Appels A. An interview to measure vital exhaustion. II. reliability and validity of the interview and correlations of vital exhaustion with personality characteristics. Psychol Health. 1996;11(4):573–81.
Morean ME, Lederman IR. Prevalence and correlates of medical cannabis patients’ use of cannabis for recreational purposes. Addict Behav. 2019;93:233–9.
Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019. JAMA Netw Open. 2023;6(1):e2254573.
Noori A, Miroshnychenko A, Shergill Y, Ashoorion V, Rehman Y, Couban RJ, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7):e047717.
Olfson M, Wall MM, Liu SM, Blanco C. Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. Am J Psychiatry. 2018;175(1):47–53.
Park JY, Wu LT. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug Alcohol Depend. 2017;177:1–13.
Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31(5):569–75.
Prins A, Bovin MJ, Smolenski DJ, Marx BP, Kimerling R, Jenkins-Guarnieri MA, et al. The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): Development and Evaluation Within a Veteran Primary Care Sample. J Gen Intern Med. 2016;31(10):1206–11.
PROMIS SF v2.0-Emotional Support 4a [Internet]. [cited 2020 Apr 22]. Available from: http://www.healthmeasures.net/search-view-measures?task=Search.search.
Rhee TG, Rosenheck RA. Opioid analgesic use and its sequelae: Opioid and other substance use disorders. Early Interv Psychiatry. 2021;15(4):975–82.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
Scherrer JF, Ahmedani B, Autio K, Debar L, Lustman PJ, Miller-Matero LR, et al. The Prescription Opioids and Depression Pathways Cohort Study. J Psychiatr Brain Sci. 2020;5.
Scherrer JF, Salas J, Miller-Matero LR, Sullivan MD, Ballantyne JC, Debar L, et al. Long-term prescription opioid users’ risk for new-onset depression increases with frequency of use. Pain. 2022;163(8):1581–9.
Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
Sullivan MD. Who gets high-dose opioid therapy for chronic non-cancer pain? Pain. 2010;151(3):567–8.
Wadsworth E, Hines LA, Hammond D. Legal status of recreational cannabis and self-reported substitution of cannabis for opioids or prescription pain medication in Canada and the United States. Subst Abus. 2022;43(1):943–8.
Wen J, Wen H, Butler JS, Talbert JC. The impact of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance. Health Econ. 2021;30(5):989–1000.
Williams N. The GAD-7 questionnaire. Occup Med. 2014;64(3):224.
Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273–7.
